RxDoctor Payments Data

Richard Perez Perez, MD

Internal Medicine · Miami, FLNPI 1821331612

Payments from drug & device makers

$3,482,555in general payments, 2019–2025

Across 52 payments — averaging $66,972 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$3.1M
  • Pfizer$295K
  • AstraZeneca$94K
  • Boston Scientific$175
  • Sanara Medtech Inc.$145
  • Collegium Pharmaceutical, Inc.$44
$885in research payments, 2019–2025

Across 10 payments — averaging $88.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$885

What the payments were for

  • Food & beverage$364100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Regeneron30$3,093,419
Pfizer12$295,248
AstraZeneca6$93,524
Boston Scientific1$175
Sanara Medtech Inc.1$145
Collegium Pharmaceutical, Inc.2$44

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,482,555 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$87,046
Medicare patients
432
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →